Earnings Call Intelligence Subscribe
Home › Call Sheets › AMGN › Q4'25
Call sheet · Q4'25

Amgen (AMGN)

Q4'25 earnings call · held February 3, 2026 · compared with the Q3'25 call · management-credibility review
9/12
Disclosure score
-
Financial quality
Bottom line
The sleeper story is biosimilars emerging as a legitimate $3B growth engine while everyone obsesses over Maritide's timeline uncertainty. Management delivered on 2025 promises but is getting cagey about Maritide maintenance data and Opaziran readouts - the binding constraint isn't demand, it's proving durability for monthly/quarterly dosing paradigms. 'We were surprised by the FDA request' on Tavneos reveals integration blind spots that could surface elsewhere. The business is fundamentally strong with 14 blockbuster products and industry-leading margins, but timeline credibility is fraying on the two biggest pipeline bets. My view changes if they provide specific Maritide maintenance data timeline or Opaziran event accrual rates - otherwise this becomes a 'trust us' story at premium valuations.

The 30-second version

  • SLEEPER STORY: Biosimilars are the quiet growth engine everyone's ignoring
  • Maritide hype meets reality: Six Phase III studies but no maintenance data timeline
  • Tavneos FDA withdrawal request is a sleeper red flag for acquisition integration

What changed this quarter

MetricQ3'25Q4'25Change
Total Revenue$9.6B (+12% YoY) Q3$37.5B est FY (+10% YoY)Solid double-digit growth maintained
Non-GAAP Operating Margin47% Q346% FY100 bps compression from R&D surge
R&D Spending+31% YoY Q3$7.2B FY (+22% YoY)Record spend but deceleration from Q3 pace
Biosimilars Revenue$775M Q3 (+52% YoY)$3B annualized (+37% YoY)Massive growth driver being underappreciated
Repatha Sales$794M Q3 (+40% YoY)$3B+ annualized (+36% YoY)Slight deceleration but Vesalius data catalyst coming
Rare Disease Portfolio$1.4B Q3 (+13% YoY)$5.2B FY (+14% YoY)Consistent mid-teens growth across portfolio
UPLIZNA Sales$155M Q3 (+46% YoY)$655M FY (+73% YoY)Explosive growth with gMG approval catalyst
Tezspire Sales$377M Q3 (+40% YoY)$1.5B FY (+52% YoY)Acceleration continues with COPD studies advancing
Free Cash Flow$4.2B Q3$8.1B FYStrong cash generation despite R&D surge
Capital Expenditures$2.2-2.3B guidance 2025$2.6B guidance 202617% increase for Maritide manufacturing prep

Accountability tracked

8 new promises made4 narrative shifts flagged7 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full AMGN Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.